Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis

To investigate the clinicopathological features and survival outcomes between young and old patients with gastric cancer (GC), and further determine the role of young age in the prognosis of GC.

Patients with stage I–III gastric adenocarcinomas undergoing curative surgery were enrolled, divided into young (aged 18–49 years, YG), middle-aged (50–59 years, MG), and old (≥ 60 years, OG) groups. Exclusion criteria were neoadjuvant therapy and history of malignant tumors. Clinicopathological features, overall survival (OS), disease-free survival (DFS), and recurrence patterns were compared among three groups.

1131 patients were finally included, with 270, 314, and 547 cases in the YG, MG, and OG, respectively. Compared to others, YG had higher proportion of female, middle-third gastric cancer, poor differentiation, N3b stage, and adjuvant chemotherapy. YG demonstrated poorer 5-year OS than MG (62.4% vs. 70.8%, P = 0.019), but better than OG (62.4% vs. 58.7%, P = 0.031). YG also suffered inferior 5-year DFS (75.2% vs. 82.8%, P = 0.040) compared with MG, and higher incidence of peritoneal recurrence than MG (15.1% vs. 5.2%, P < 0.001) and OG (15.1% vs. 4.1%, P < 0.001). Multivariate analysis identified young age as the independent prognostic factor for OS [hazard ratio (HR) = 1.347, 95% CI 1.018–1.781, P = 0.037], DFS (HR = 1.601, 95% CI 1.079–2.376, P = 0.019), and peritoneal recurrence (HR = 2.936, 95% CI 1.505–5.726, P = 0.002).

Young GC patients demonstrated aggressive features with poor prognosis and enhanced management may be warranted for this subgroup.